Opportunities and challenges of incretin-based hypoglycemic agents treating type 2 diabetes mellitus from the perspective of physiological disposition

导出学术成果认领

作者 Yaochen Xie ^[1] Qian Zhou ^[2] Qiaojun He ^[1] Xiaoyi Wang ^[3] Jincheng Wang ^[1] 学术成果认领

作者单位 Center for Drug Safety Evaluation and Research,Zhejiang Province Key Laboratory of Anti-Cancer Drug Research,College of Pharmaceutical Sciences,Zhejiang University,Hangzhou 310007,China ^[1] Department of Pharmacy,Hangzhou Medical College,Hangzhou 310053,China ^[2] Department of Nephrology,the First Affiliated Hospital of Huzhou Teachers College,the First People's Hospital of Huzhou,Hangzhou 313000,China ^[3]

关键词 T2DM Incretins-based hypoglycemic agents GLP-1 receptor agonists DPP-4 inhibitors Physiological disposition Metabolism Excretion Drug-drug interactions

栏目名称 Reviews

DOI 10.1016/j.apsb.2022.11.008

发布时间 2023-08-08

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览1
被引0
下载0

药学学报（英文版）

2023年13卷6期

2383-2402页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Opportunities and challenges of incretin-based hypoglycemic agents treating type 2 diabetes mellitus from the perspective of physiological disposition

药学学报（英文版）

相似文献

药学学报（英文版）

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Opportunities and challenges of incretin-based hypoglycemic agents treating type 2 diabetes mellitus from the perspective of physiological disposition

药学学报（英文版）

相似文献

药学学报（英文版）

相关期刊

检索历史清除